We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+8.6%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.35B
AUM Growth
+$157M
(+13%)
Cap. Flow
+$100M
Cap. Flow
% of AUM
7.42%
Top 10 Holdings %
Top 10 Hldgs %
27.65%
Holding
142
New
12
Increased
63
Reduced
5
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$21.7M |
| 2 |
Cigna
CI
|
+$11.2M |
| 3 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$10.4M |
| 4 |
CLSD
Clearside Biomedical
CLSD
|
+$9.46M |
| 5 |
HOLX
Hologic
HOLX
|
+$7.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$32.7M |
| 2 |
Elevance Health
ELV
|
+$16.8M |
| 3 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$9.49M |
| 4 |
Cooper Companies
COO
|
+$7.33M |
| 5 |
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
+$5.78M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.95% |
| 2 | Financials | 3.98% |
| 3 | Industrials | 0.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATYR
126
aTyr Pharma
ATYR
$50.1M
| $1.21M | 0.09% |
30,964
| – | – |
|
|
CERN
127
DELISTED
Cerner Corp
CERN
| $1.17M | 0.09% |
+20,000
| New | +$1.11M |
|
|
SPHS
128
DELISTED
Sophiris Bio, Inc.
SPHS
| $1.05M | 0.08% |
490,000
-138,563
| -22% | -$191K |
|
129
Puma Biotechnology
PBYI
$454M
| $983K | 0.07% |
33,000
+1,500
| +5% | +$46.9K |
|
|
BLUE
130
DELISTED
bluebird bio
BLUE
| $866K | 0.06% |
1,544
| – | – |
|
|
OREX
131
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $711K | 0.05% |
165,300
| – | – |
|
|
SYBX
132
DELISTED
Synlogic
SYBX
| $639K | 0.05% |
1,429
| – | – |
|
|
INFI
133
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $359K | 0.03% |
270,000
| – | – |
|
|
134
Cooper Companies
COO
$14.5B
| – | – |
-190,400
| Closed | -$7.33M |
|
|
135
Elevance Health
ELV
$85.5B
| – | – |
-121,000
| Closed | -$16.8M |
|
|
PTLA
136
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-35,000
| Closed | -$714K |
|
|
BXLT
137
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| – | – |
-810,000
| Closed | -$32.7M |
|
|
ANAC
138
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| – | – |
-177,500
| Closed | -$9.49M |
|
Similar funds
ACM
BCM
PP
GAM
FACM
RMC
JIP
II
Rock Springs Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Rock Springs Capital Management held 142 positions worth $1.35B, up 13% from $1.19B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Rock Springs Capital Management deployed $100M of net new capital in Q2 2016, opening 12 new positions and adding to 63 existing holdings. Its largest new stake was Shire pic: 120,042 shares worth $22.1M.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Inovalon Holdings, Inc. Class A Common Stock, an estimated $5.78M trimmed.
- Rock Springs Capital Management's largest Q2 2016 buy was Shire pic: 120,042 shares worth $22.1M.
- Rock Springs Capital Management added most to Cigna in Q2 2016, an estimated $11.2M increase.
- Rock Springs Capital Management's biggest Q2 2016 reduction was Inovalon Holdings, Inc. Class A Common Stock, cutting an estimated $5.78M.
- Rock Springs Capital Management fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $32.7M.
- Rock Springs Capital Management's ten largest holdings make up 28% of its $1.35B portfolio in Q2 2016.
- Rock Springs Capital Management opened 12 new positions and closed 5 in Q2 2016.
- Rock Springs Capital Management's portfolio value rose 13% quarter-over-quarter to $1.35B.
Based on Rock Springs Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.